US Stock MarketDetailed Quotes

IMTX Immatics

Watchlist
  • 10.010
  • +0.230+2.35%
Close Apr 26 16:00 ET
1.03BMarket Cap-7802P/E (TTM)

About Immatics Company

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics. The company was founded on March 10, 2020, and is headquartered in Tuebingen, Germany.

Company Profile

SymbolIMTX
Company NameImmatics
Listing DateJul 2, 2020
Issue Price10.00
Founded2020
CEODr. Harpreet Singh, PhD
MarketNASDAQ
Employees343
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
AddressPaul-Ehrlich-Strasse 15
CityTuebingen
ProvinceBaden Wuerttemberg
CountryGermany
Zip Code72076
Phone49-7071-5397-0
Websitehttp://www.immatics.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Harpreet Singh, PhD
  • Director and Chief Executive Officer
  • 7.50M
  • Arnd Christ
  • Chief Financial Officer
  • --
  • Dr. Cedrik Britten, M.D.
  • Chief Medical Officer
  • --
  • Dr. Steffen Walter, PhD
  • Chief Operations Officer
  • --
  • Dr. Carsten Reinhardt,M.D.,PhD
  • Chief Development Officer
  • --
  • Dr. Toni Weinschenk, PhD
  • Chief Innovation Officer
  • --
  • Dr. Rainer Kramer, PhD
  • Chief Business Officer
  • --
  • Peter Alan Chambre
  • Chairman of the Board
  • 283.00K
  • Edward Sturchio, J.D.
  • General Counsel
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg